Johnson & Johnson
JNJ | NYSE
$282.55
-$3.20 (-1.12%)
At close: Nov 16, 2026, 4:00 PM ET
$282.55
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:51 PM ET
Johnson & Johnson Company Profile
Company profile explainedCompany Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Key Executives
| Name | Position |
|---|---|
| Joaquin Duato | Chief Executive Officer & Chairman |
| Elizabeth Forminard | Executive Vice President & Chief Legal Officer |
| James Swanson | Executive Vice President & Chief Information Officer |
| Joseph J. Wolk | Executive Vice President & Chief Financial Officer |
| Dirk Brinckman | Chief Compliance Officer |
| John C. Reed | Executive Vice President of Innovative Medicine and R&D |
| Kathryn E. Wengel | Executive Vice President and Chief Technical Operations & Risk Officer |
| Kristen Blair Mulholland | Executive Vice President & Chief Human Resources Officer |
| Robert J. Decker Jr. | Controller & Chief Accounting Officer |
| Ryan Koors | Vice President of Investor Relations |
| Timothy Schmid | Executive Vice President & Worldwide Chairman of MedTech |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | 13F-HR | Quarterly report filed by institutional managers, ... |
| Oct 21, 2026 | 10-Q | Quarterly Report |
| Oct 13, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 01, 2026 | 3 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
Johnson & Johnson
| Country | United States |
| IPO Date | Jan 2, 1962 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 141,700 |
| CEO | Joaquin Duato |
Contact Details
One Johnson & Johnson Plaza New Brunswick,
New Jersey 08933 United States
Stock Details
| Ticker Symbol | JNJ |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000200406 |
| CUSIP Number | 478160104 |
| ISIN Number | US4781601046 |
| SIC Code | 2834 |
Recent News
- 15 hours ago / zacks.comJ&J Stock Rallies More Than 10% in a Month: Time to Buy, Sell or Hold?
- 18 hours ago / gurufocus.comJohnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
- 18 hours ago / wsj.comJohnson & Johnson to Buy Ollin Biosciences for $2.2 Billion
- 3 days ago / 247wallst.comHow Much Does a 69-Year-Old Need Invested in Dividend Stocks to Collect $3,000 a Month?
- 4 days ago / youtube.comThe Big 3: JNJ, LLY, AAPL
- 4 days ago / zacks.comJohnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue?
- 5 days ago / fool.comJohnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?
- 5 days ago / fool.comJohnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?
- 5 days ago / businesswire.comMassachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case
- 6 days ago / zacks.comJ&J's Oncology Sales Surge So Far in 2026: What Lies Ahead?
Add to Watchlist
Select watchlists to add or remove JNJ